Roche Holding AG (FRA:RHO)
Germany
· Delayed Price · Currency is EUR | Market Cap | 323.07B |
| Revenue (ttm) | 68.05B |
| Net Income (ttm) | 13.83B |
| Shares Out | n/a |
| EPS (ttm) | 17.23 |
| PE Ratio | 23.35 |
| Forward PE | 18.02 |
| Dividend | 9.70 (2.32%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 31 |
| Average Volume | 72 |
| Open | 402.80 |
| Previous Close | 405.60 |
| Day's Range | 402.80 - 418.00 |
| 52-Week Range | 270.20 - 418.00 |
| Beta | n/a |
| RSI | 67.27 |
| Earnings Date | Apr 24, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Quantum Strategy's David Roche thinks Iran regime could be 'gone within a year'
David Roche of Quantum Strategy explains why he believes Iran's current regime could fall within a year. He also says he does not see Tehran conceding to U.S. demands to limit its nuclear program, vie...
ClearBridge International Growth ACWI Ex-US Strategy adds and exits multiple positions
ClearBridge International Growth ACWI ex-US Q4 2025 recap: performance vs MSCI index, plus key buys and sells (Roche, ASML, Ryanair).
The Zacks Analyst Blog Highlights Costco Wholesale, Roche, Lam Research, Spruce Power and IDT
Costco, Roche and Lam Research lead Zacks??? top stock reports, with standout gains and resilient fundamentals across sectors.
Roche (RHHBY) Awaits FDA Decision on Giredestrant for Breast Cancer
Roche (RHHBY) Awaits FDA Decision on Giredestrant for Breast Cancer
Roche granted FDA review for novel breast cancer therapy
FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.'s (NYSE: ABBV) combination treatment for chronic lymphocytic leukemia (CLL). The FDA has approved the combination of Vencle...
FDA Approves Genentech's Venclexta And Acalabrutinib Combo For Untreated CLL
(RTTNews) - Genentech, a member of the Roche Holding AG (RHHBY), said on Friday that the U.S. Food and Drug Administration has approved the combination of Venclexta plus acalabrutinib for the treatmen...
FDA Approves Genentech's Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the com...
FDA Accepts New Drug Application for Genentech's Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
FDA accepts New Drug Application for Roche's giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Basel, 20 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States (U.S.) Food and Drug Administration (FDA) has accepted the company's New Drug Application for girede...
Change to the Roche Enlarged Corporate Executive Committee
Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Mark Dawson, M.D., Ph.D., as the new Head of Roche Pharma Research and Early Development (pRED), effecti...
Genentech Reports Positive Phase III Results For Gazyva In Primary Membranous Nephropathy
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that the Phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistically sig...
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
Basel, 16 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistica...
Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MAJESTY study in adults with primary membranous nep...
Roche Holding AG (RHHBY) Shareholder/Analyst Presentation
2026-02-09. The following slide deck was published by Roche Holding AG in conjunction with this event.
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Says Experimental Drug Helped Slow Disability In Progressive Multiple Sclerosis Study
Roche Holdings AG (OTC: RHHBY) on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib. Fenebrutinib is a...
Roche's (RHHBY) Fenebrutinib Shows Promise in Phase 3 MS Trial
Roche's (RHHBY) Fenebrutinib Shows Promise in Phase 3 MS Trial
Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial
Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal in a late-stage trial in patients with primary progressive multiple sclerosi...
Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Basel, 07 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK) inhibi...
Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the...
Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in red...
Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc...
These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys?
Weight loss candidates from Amgen and Roche performed well in phase 2 studies. These could be exciting additions to these companies' drug portfolios.
ClearBridge International Growth ADR Strategy exits Linde, adds Roche in Q4 2025
ClearBridge International Growth ADR Strategy underperformed its primary MSCI EAFE benchmark for the fourth quarter of 2025, and slightly underperformed its secondary MSCI EAFE Growth benchmark.